Synthesis and evaluation of thiopyrano[3,4-c]quinoline-9-carboxamide derivatives as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1)

详细信息    查看全文

• 作者：Chun-Ho Park (1) (3)
  Kwangwoo Chun (1)
  Bo-Young Joe (1)
  Jong-Hee Choi (1)
  Han-Chang Lee (1)
  Il-Whea Ku (1)
  Hyun Young Kim (2)
  Seong-Ho Koh (2)
  Goang Won Cho (2)
  Seung Hyun Kim (2)
  Myung-Hwa Kim (1)
  
• 关键词：Poly(ADP ; ribose)polymerase ; PARP ; 1 inhibitor ; Thiopyranoquinoline derivatives
• 刊名：Medicinal Chemistry Research
• 出版年：2012
• 出版时间：August 2012
• 年：2012
• 卷：21
• 期：8
• 页码：1533-1543
• 全文大小：355KB
• 参考文献：1. Alano CC, Ying W, Swanson RA (2004) Poly(ADP-ribose) polymerase-1-mediated cell death in astrocytes requires NAD+ depletion and mitochondrial permeability transition. J Biol Chem 279(18):18895-8902 CrossRef
  2. Calabrese CR, Batey MA, Thomas HD, Durkacz BW, Wang LZ, Kyle S, Skalitzky D, Li J, Zhang C, Boritzki T, Maegley K, Calvert AH, Hostomsky Z, Newell DR, Curtin NJ (2003) Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res 9(7):2711-718
  3. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang LZ, Webber SE, Williams KJ, Curtin NJ (2004) Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96(1):56-7 CrossRef
  4. D’Amours D, Desnoyers S, D’Silva I, Poirier GG (1999) Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 342(Pt 2):249-68 CrossRef
  5. Ferraris DV (2010) Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J Med Chem 53(12):4561-584 CrossRef
  6. Ha HC, Snyder SH (1999) Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci USA 96(24):13978-3982 CrossRef
  7. Ishida J, Yamamoto H, Kido Y, Kamijo K, Murano K, Miyake H, Ohkubo M, Kinoshita T, Warizaya M, Iwashita A, Mihara K, Matsuoka N, Hattori K (2006) Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling. Bioorg Med Chem 14(5):1378-390 CrossRef
  8. Khuthier AH, Al-Mallah KY, Hanna SY, Abdulla NAI (1987) Studies of tertiary amine oxides. 9. Thermal rearrangement of 1-(4-substituted-phenyl)piperidine / N-oxide to the corresponding / N-hydroxylamines. J Org Chem 52(9):1710-713 CrossRef
  9. Kinoshita T, Nakanishi I, Warizaya M, Iwashita A, Kido Y, Hattori K, Fujii T (2004) Inhibitor-induced structural change of the active site of human poly(ADP-ribose) polymerase. FEBS Lett 556(1-):43-6 CrossRef
  10. Lee S, Koo HNand Lee BH (2005) Development of a miniaturized assay for the high-throughput screening program for poly(ADP-ribose) polymerase-1. Methods and findings in experimental and clinical pharmacology. Methods Find Exp Clin Pharmacol 27(9):617-22 CrossRef
  11. Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia J, de Murcia G (1998) XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol 18(6):3563-571
  12. Matsumoto K, Kondo K, Ota T, Kawashima A, Kitamura K, Ishida T (2006) Binding mode of novel 1-substituted quinazoline derivatives to poly(ADP-ribose) polymerase-catalytic domain revealed by X-ray crystal structure analysis of complexes. Biochim Biophys Acta 1764(5):913-19
  13. Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, Javaid H, Kerrigan F, Knights C, Lau A, Loh VM Jr, Matthews IT, Moore S, O’Connor MJ, Smith GC, Martin NM (2008) 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2 / H-phth alazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 51(20):6581-591 CrossRef
  14. Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W, Ator M, Bihovsky R, Hudkins R, Chatterjee S, Klein-Szanto A, Dionne C, Ruggeri B (2003) Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2(4):371-82 CrossRef
  15. Nakamura J, Asakura S, Hester SD, de Murcia G, Caldecott KW, Swenberg JA (2003) Quantitation of intracellular NAD(P)H can monitor an imbalance of DNA single strand break repair in base excision repair deficient cells in real time. Nucleic Acids Res 31(17):e104 CrossRef
  16. Park CH, Chun K, Joe BY, Park JS, Kim YC, Choi JS, Ryu DK, Koh SH, Cho GW, Kim SH, Kim MH (2010) Synthesis and evaluation of tricyclic derivatives containing a non-aromatic amide as inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1). Bioorg Med Chem Lett 20(7):2250-253 CrossRef
  17. Penning TD, Zhu GD, Gandhi VB, Gong J, Liu X, Shi Y, Klinghofer V, Johnson EF, Donawho CK, Frost DJ, Bontcheva-Diaz V, Bouska JJ, Osterling DJ, Olson AM, Marsh KC, Luo Y, Giranda VL (2009) Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1 / H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem 52(2):514-23 CrossRef
  18. Sandhu SK, Yap TA, de Bono JS (2010) Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer 46(1):9-0 CrossRef
  19. Stork G, Brizzolara A, Landesman H, Szmuszkovicz J, Terrell R (1963) The emamine alkylation and acylation of carbonyl compounds. J Am Chem Soc 85:207-22 CrossRef
  20. Strosznajder RP, Jesko H, Zambrzycka A (2005) Poly(ADP-ribose) polymerase: the nuclear target in signal transduction and its role in brain ischemia-reperfusion injury. Mol Neurobiol 31(1-):149-67 CrossRef
  21. Tentori L, Graziani G (2005) Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 52(1):25-3 CrossRef
  22. Tentori L, Leonetti C, Scarsella M, D’Amati G, Portarena I, Zupi G, Bonmassar E, Graziani G (2002a) Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood 99(6):2241-244 CrossRef
  23. Tentori L, Portarena I, Graziani G (2002b) Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res 45(2):73-5 CrossRef
  24. Tentori L, Leonetti C, Scarsella M, D’Amati G, Vergati M, Portarena I, Xu W, Kalish V, Zupi G, Zhang J, Graziani G (2003) Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 9(14):5370-379
  25. Virag L, Szabo C (2002) The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54(3):375-29 CrossRef
  26. Ying W, Alano CC, Garnier P, Swanson RA (2005) NAD+ as a metabolic link between DNA damage and cell death. J Neurosci Res 79(1-):216-23 CrossRef
  
• 作者单位：Chun-Ho Park (1) (3)
  Kwangwoo Chun (1)
  Bo-Young Joe (1)
  Jong-Hee Choi (1)
  Han-Chang Lee (1)
  Il-Whea Ku (1)
  Hyun Young Kim (2)
  Seong-Ho Koh (2)
  Goang Won Cho (2)
  Seung Hyun Kim (2)
  Myung-Hwa Kim (1)
  
  1. Drug Discovery Laboratory, R&D Center, Jeil Pharmaceutical Co., Ltd, 117-1, Keungok-Ri, Baekam-Myun, Cheoin-Gu, Yongin-City, Kyunggi-Do, 449-861, Republic of Korea
  3. Graduate Program in Biomaterials Science and Engineering, Yonsei University, Seodaemun-Gu, Seoul, 120-740, Republic of Korea
  2. Department of Neurology, Hanyang University College of Medicine, Seoul, Republic of Korea
  

文摘

A series of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors, 5-oxo-2,4,5,6-tetrahydro-1H-thiopyrano[3,4-c]quinoline-9-carboxamide derivatives, were successfully synthesized and their PARP-1 inhibitory activity was evaluated. These compounds were prepared from carboxylic acid 7 and the appropriate amines, and a number of the synthesized compounds were found to have significant PARP-1 activity. Among them, 9m showed potent activity in a PARP-1 enzymatic assay and cell-based assay (IC50?=?0.045?μM, ED50?=?0.54?μM). Molecular modeling studies confirmed the obtained biological results.